Citigroup
VYNE icon

Citigroup’s VYNE Therapeutics VYNE Stock Holding History

Citigroup’s Portfolio VYNE Stock Details VYNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-2,222
Closed -$16K – 6360
2022
Q2 		$16K Buy
2,222
+2,155
+3,216% +$18.1K ﹤0.01% 5133
2022
Q1 		$1K Buy
+67
New +$796 ﹤0.01% 6224
2021
Q4 		– Sell
-161
Closed -$4K – 6111
2021
Q3 		$4K Sell
161
-12
-7% -$465 ﹤0.01% 5619
2021
Q2 		$11K Sell
173
-8,114
-98% -$642K ﹤0.01% 5635
2021
Q1 		$1.02M Buy
8,287
+7,833
+1,725% +$1.14M ﹤0.01% 2971
2020
Q4 		$52K Buy
454
+357
+368% +$44.9K ﹤0.01% 6018
2020
Q3 		$12K Sell
97
-101
-51% -$11.8K ﹤0.01% 6519
2020
Q2 		$25K Sell
198
-10
-5% -$1.35K ﹤0.01% 6455
2020
Q1 		$40K Buy
208
+158
+316% +$49.6K ﹤0.01% 6182
2019
Q4 		$17K Buy
50
+30
+150% +$10K ﹤0.01% 7002
2019
Q3 		$7K Sell
20
-35
-64% -$11.3K ﹤0.01% 7229
2019
Q2 		$24K Buy
55
+22
+67% +$10.9K ﹤0.01% 6998
2019
Q1 		$19K Sell
33
-3
-8% -$1.44K ﹤0.01% 6996
2018
Q4 		$10K Sell
36
-1
-3% -$448 ﹤0.01% 7163
2018
Q3 		$26K Buy
37
+19
+106% +$11.7K ﹤0.01% 6963
2018
Q2 		$10K Buy
18
+6
+50% +$4.66K ﹤0.01% 7198
2018
Q1 		$32K Buy
+12
New +$29.2K ﹤0.01% 6469

Other funds holding VYNE

DA
DSC Advisors Chicago, Illinois $11M AUM 5.88% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
CAN
Cetera Advisor Networks El Segundo, California $20.2B AUM 22.31% 1-Year Est. Return

Citigroup's VYNE Position: Q3 2022 in Review

Citigroup sold out of VYNE Therapeutics (VYNE) in Q3 2022, closing a stake of 2,222 shares — an estimated $16K sold.

Citigroup first reported a position in VYNE in Q1 2018 and held it in 17 quarters. The position peaked at $1.02M in Q1 2021. 41 funds tracked by Wall St. Rank hold VYNE as of Q3 2022.

  • Citigroup reported no remaining VYNE Therapeutics position as of Q3 2022 after selling out during the quarter.
  • Citigroup sold 2,222 VYNE Therapeutics shares in Q3 2022, an estimated $16K.
  • Citigroup first reported a position in VYNE Therapeutics in Q1 2018 and held it in 17 quarters.
  • Citigroup's VYNE Therapeutics position peaked at $1.02M in Q1 2021.
  • 41 funds tracked by Wall St. Rank held VYNE Therapeutics as of Q3 2022.

Based on Citigroup's 13F filing for Q3 2022, filed 10 Nov 2022.